MedPath

Daxor Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:4

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

BVA-200 vs BVA-100 Validation Study

Completed
Conditions
Kidney Diseases
Trauma
Other Disease
Clotting Disorder
High Cholesterol
Thyroid Diseases
Heart Failure
Anemia
Diabetes
High Blood Pressure
First Posted Date
2024-01-29
Last Posted Date
2024-01-29
Lead Sponsor
Daxor Corporation
Target Recruit Count
62
Registration Number
NCT06227819
Locations
🇺🇸

Daxor Corporation, Oak Ridge, Tennessee, United States

Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure

Not Applicable
Completed
Conditions
Acute Decompensated Heart Failure
First Posted Date
2021-04-22
Last Posted Date
2023-09-29
Lead Sponsor
Daxor Corporation
Target Recruit Count
32
Registration Number
NCT04855097
Locations
🇺🇸

VA Boston Healthcare System, Boston, Massachusetts, United States

Monitoring Outpatient Blood VolumE in Heart Failure

Completed
Conditions
Heart Failure
First Posted Date
2020-12-09
Last Posted Date
2023-09-29
Lead Sponsor
Daxor Corporation
Target Recruit Count
15
Registration Number
NCT04660396
Locations
🇺🇸

Geisinger, Danville, Pennsylvania, United States

Total Body Albumin Measurement Utilizing a Modification of the BVA 100 Blood Volume Analyzer

Completed
Conditions
Hypoalbuminemia
Heart Failure
Nephrosis
Cirrhosis
Shock
First Posted Date
2012-03-02
Last Posted Date
2012-03-02
Lead Sponsor
Daxor Corporation
Target Recruit Count
20
Registration Number
NCT01542749

News

Daxor Submits FDA 510(k) for Next-Generation Blood Volume Analyzer with Enhanced Point-of-Care Capabilities

Daxor Corporation has submitted its next-generation blood volume analyzer (Daxor BVA) to the FDA for 510(k) clearance, designed to process tests three times faster than its predecessor.

Blood Volume Analysis Outperforms Traditional Methods in Heart Failure Assessment, Multicenter Study Shows

A new multicenter study across three major medical institutions demonstrates Daxor's Blood Volume Analysis (BVA) provides superior accuracy over conventional pressure-based measurements in heart failure patients.

© Copyright 2025. All Rights Reserved by MedPath